Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis

Keyphrases

• Apoptosis 100%
• Prostate Cancer Cells 100%
• Hormone-sensitive Prostate Cancer 100%
• Actinomycin D 100%
• Gemcitabine 100%
• Apo2L 100%
• Human Prostate Cancer Cells 20%
• Paclitaxel 20%
• Cis-platinum 20%
• LNCaP 20%
• Monoclonal Antibody 10%
• Killing Activity 10%
• Incubation 10%
• Sensitizer 10%
• Induced Apoptosis 10%
• Tumor Cells 10%
• Synergistic Index 10%
• Tumor Necrosis Factor-α 10%
• Necrosis 10%
• Fas Ligand 10%
• Prostate Cancer 10%
• Ligand-mediated 10%
• Biphasic Pattern 10%
• Drug Refractory 10%
• Cytotoxic Efficacy 10%
• VP16 10%
• TRAIL Receptors 10%
• Tumor Necrosis Factor Ligand 10%
• Hormone Refractory 10%
• DU145 10%
• PC-3 Cell Line 10%
• Antifa 10%
• Cancer Cell Resistance 10%
• Synergistic Sensitization 10%

Medicine and Dentistry

• Cancer Cell 100%
• Programmed Cell Death 100%
• Androgen 100%
• Prostate Cancer 100%
• Dactinomycin 100%
• Gemcitabine 100%
• Sensitization 71%
• Tumor Necrosis Factor 28%
• Cisplatin 28%
• Cell Line 28%
• Paclitaxel 28%
• Incubation 14%
• Tumor Cell 14%
• Monoclonal Antibody 14%
• Necrosis 14%
• Fas Ligand 14%
• Prostate Cancer Cell Line 14%
• Tumor Necrosis Factor Related Apoptosis Inducing Ligand Receptor 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Androgen 100%
• Dactinomycin 100%
• Gemcitabine 100%
• Tumor Necrosis Factor 40%
• Cisplatin 40%
• Paclitaxel 40%
• Neoplasm 20%
• Monoclonal Antibody 20%
• Necrosis 20%
• Fas Ligand 20%
• Tumor Necrosis Factor Related Apoptosis Inducing Ligand Receptor 20%